PT Kalbe Farma Tbk. (PTKFY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PT Kalbe Farma Tbk. (PTKFY) trades at $8.69 with AI Score 47/100 (Grade C). PT Kalbe Farma Tbk. Market cap: $9.84M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for PTKFY: PTKFY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PTKFY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PTKFY: the 1 perspectives are evenly split.
How is this calculated? →PT Kalbe Farma Tbk. (PTKFY) Healthcare & Pipeline Overview
PT Kalbe Farma Tbk. is a prominent Indonesian pharmaceutical company offering a wide array of products, including prescription drugs, over-the-counter medications, and nutritional solutions, positioning itself as a leader in the healthcare sector with a commitment to innovation and quality.
What Is the Investment Thesis for PTKFY?
PT Kalbe Farma Tbk. presents a solid investment thesis driven by its diversified product portfolio and strong market presence in Indonesia's healthcare sector. With a market capitalization of $9.84M and a P/E ratio of 9.1, the company maintains a profit margin of 10.0% and a gross margin of 38.7%. Growth catalysts include the increasing demand for healthcare products in emerging markets, particularly in the nutritional segment, which serves a broad demographic. The company's ongoing investments in research and development, alongside its comprehensive distribution network, are expected to enhance its competitive advantage. However, potential risks include currency fluctuations that may impact the valuation of its ADR and regulatory changes in the Indonesian pharmaceutical landscape. Monitoring these factors will be crucial for assessing the company's future performance.
Based on FMP financials and quantitative analysis
PTKFY Key Highlights
- Market Cap of $9.84M with a P/E ratio of 9.1, indicating a potentially undervalued stock.
- Profit margin of 10.0%, reflecting effective cost management and operational efficiency.
- Gross margin of 38.7%, exceeding industry averages and showcasing strong pricing power.
- Dividend yield of 2.70%, providing a steady income stream for investors.
- Beta of -0.04, indicating low volatility compared to the market.
Who Are PTKFY's Competitors?
PTKFY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| UNVR Univar Solutions Inc. | $36.14 | +0.47% | $5.70B | 54 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| SNPHF Santen Pharmaceutical Co., Ltd. | $10.99 | -15.79% | $3.54B | 47 |
| PTKFF PT Kalbe Farma Tbk. | $0.04 | +11.41% | $2.03B | 47 |
| SNYNF Sanofi | $85.25 | +0.64% | $102.48B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PTKFY's Key Strengths?
- Leading market position in Indonesia's pharmaceutical sector.
- Strong brand recognition and customer loyalty.
- Diverse product offerings catering to various health needs.
- Robust distribution network across the country.
What Are PTKFY's Weaknesses?
- Dependence on the Indonesian market for revenue.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes affecting operations.
- Exposure to currency fluctuations impacting ADR valuations.
What Could Drive PTKFY Stock Higher?
- Expansion of nutritional product lines to meet growing health demands.
- Investment in contract research services to enhance revenue streams.
- Potential entry into international markets to diversify revenue.
- Continuous innovation in product development to maintain competitive edge.
- Strategic partnerships with healthcare providers to enhance service offerings.
What Are the Key Risks for PTKFY?
- Currency fluctuations impacting ADR valuations.
- Regulatory changes affecting product approvals and market access.
- Economic downturns reducing consumer spending on healthcare products.
- Intense competition from local and international pharmaceutical companies.
What Are the Growth Opportunities for PTKFY?
- Growth opportunity 1: The nutritional products segment is poised for substantial growth, projected to reach $6 billion by 2028, driven by increasing health consciousness among consumers. Kalbe Farma's established brand and diverse product offerings position it favorably to capture this expanding market.
- Growth opportunity 2: The demand for over-the-counter medications is expected to grow at a CAGR of 5% over the next five years, fueled by rising self-medication trends. Kalbe Farma's extensive portfolio in this category allows it to leverage this trend effectively.
- Growth opportunity 3: Expansion into international markets presents a significant opportunity, with Southeast Asia's pharmaceutical market projected to grow at 10% annually. Kalbe Farma's experience and established distribution channels can facilitate successful entry into new regions.
- Growth opportunity 4: The company's investment in contract research services is expected to grow as more pharmaceutical firms seek outsourcing solutions. This segment could see a market expansion of 15% over the next three years, enhancing Kalbe Farma's revenue streams.
- Growth opportunity 5: Digital health solutions are gaining traction, with the global market expected to reach $500 billion by 2025. Kalbe Farma's potential to innovate in this space could provide new revenue opportunities and enhance patient engagement.
What Opportunities Does PTKFY Have?
- Growing demand for healthcare products in emerging markets.
- Expansion into international markets for revenue diversification.
- Increasing health consciousness driving nutritional product sales.
- Potential growth in digital health solutions and services.
What Threats Does PTKFY Face?
- Intense competition from both local and international pharmaceutical companies.
- Regulatory challenges that may impact product approvals.
- Economic fluctuations affecting consumer spending on healthcare.
- Potential risks associated with supply chain disruptions.
What Are PTKFY's Competitive Advantages?
- Established brand reputation in the Indonesian pharmaceutical market.
- Diverse product portfolio addressing various health needs.
- Extensive distribution network ensuring widespread product availability.
- Strong relationships with healthcare providers and pharmacies.
- Commitment to research and development fostering innovation.
What Does PTKFY Do?
Founded in 1966 in Jakarta, Indonesia, PT Kalbe Farma Tbk. has grown to become one of the largest pharmaceutical companies in the country. The company operates through four main divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. Kalbe Farma's extensive portfolio includes a range of generic, branded, and licensed prescription medications, with notable products such as Brainact, Cefspan, and Neuralgin. These products are distributed to hospitals, pharmacies, and drugstores across Indonesia, ensuring widespread access to essential medications. In addition to prescription drugs, Kalbe Farma offers over-the-counter medicines, energy beverages, dietary supplements, and preventive health solutions, catering to a diverse demographic that includes infants, children, adults, and the elderly. The company is also involved in contract research services for pharmaceutical firms, which includes clinical study management and bioavailability assessments. Beyond pharmaceuticals, Kalbe Farma contributes to animal health and operates the Mitrasana Clinics, providing healthcare services and health screenings. The company also engages in the distribution of consumer goods, medical devices, and cosmetics, alongside trading medical and laboratory equipment. Kalbe Farma's commitment to innovation and quality has positioned it as a key player in the Indonesian healthcare market, with a focus on improving health outcomes and expanding its product offerings.
What Products and Services Does PTKFY Offer?
- Develops and manufactures prescription pharmaceuticals.
- Produces over-the-counter medications for various health needs.
- Offers nutritional products for diverse demographic groups.
- Provides contract research services for pharmaceutical companies.
- Operates healthcare clinics and offers health screening services.
- Distributes consumer goods, medical devices, and cosmetics.
How Does PTKFY Make Money?
- Generates revenue through the sale of prescription and over-the-counter medications.
- Offers nutritional products catering to various age groups and health needs.
- Provides contract research services, generating income from pharmaceutical firms.
- Operates clinics that offer health services and screenings.
- Engages in the distribution of consumer goods and medical devices.
What Industry Does PTKFY Operate In?
The pharmaceutical industry in Indonesia is experiencing significant growth, driven by increasing healthcare demands and a rising middle class. With a market size projected to expand as the government emphasizes healthcare access, PT Kalbe Farma Tbk. is well-positioned to capitalize on these trends. The competitive landscape includes both local and international players, but Kalbe Farma's established brand reputation and extensive distribution network provide a strong competitive edge. As the industry evolves, regulatory compliance and innovation will be critical for maintaining market share.
Who Are PTKFY's Key Customers?
- Hospitals and healthcare providers requiring prescription medications.
- Pharmacies and drugstores distributing over-the-counter products.
- Consumers seeking nutritional supplements and health solutions.
- Pharmaceutical companies needing contract research services.
- Individuals visiting clinics for health screenings and services.
Company Profile
PT Kalbe Farma Tbk. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Jakarta, ID. The company is led by CEO Bernadette Ruth Irawati Setiady. PTKFY has traded publicly since 2012.
F-Score 6/9Financial Health
PT Kalbe Farma Tbk.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.32 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 16%Key Financial Metrics
Return on equity for PT Kalbe Farma Tbk. stands at 15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.3%, showing how much profit it generates from its asset base. PTKFY trades at a trailing price-to-earnings ratio of 9.07, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.4%, the inverse of the P/E and a quick read on earnings relative to price.
PTKFY Valuation & Market Position
With a $9.84M market cap, PT Kalbe Farma Tbk. sits in the micro-cap segment of the market. Relative to its peer group, PTKFY's quantitative score of 47/100 is below the peer average of 61/100.
FY2026 estForward Outlook
Wall Street analysts project PT Kalbe Farma Tbk. revenue of about $38.15T for fiscal 2026, with EPS near $0.00. The estimate reflects 13 contributing analysts.
PTKFY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Leading market position in Indonesia's pharmaceutical sector.
- Strong brand recognition and customer loyalty.
- Diverse product offerings catering to various health needs.
- Robust distribution network across the country.
Bear Case
- Dependence on the Indonesian market for revenue.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes affecting operations.
- Exposure to currency fluctuations impacting ADR valuations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PTKFY Latest News
No recent news available for PTKFY.
PTKFY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PTKFY.
Price Targets
Wall Street price target analysis for PTKFY.
PTKFY MoonshotScore
What does this score mean?
The MoonshotScore rates PTKFY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Bernadette Ruth Irawati Setiady
CEO
Bernadette Ruth Irawati Setiady has extensive experience in the pharmaceutical industry, having held various leadership roles within PT Kalbe Farma Tbk. since its inception. She holds a degree in Pharmacy and has furthered her education with an MBA, equipping her with the skills necessary for strategic management. Under her leadership, the company has focused on innovation and expanding its product portfolio.
Track Record: Since becoming CEO, Bernadette has driven significant growth in Kalbe Farma's nutritional products segment and expanded the company's footprint in contract research services. Her strategic vision has led to the introduction of several successful product lines and enhanced operational efficiencies.
PT Kalbe Farma Tbk. ADR Information Unsponsored
An American Depositary Receipt (ADR) represents shares of a foreign company traded on US exchanges. PT Kalbe Farma Tbk. operates as a Level I ADR, allowing US investors to trade shares without needing to deal with foreign stock exchanges directly.
- Home Market Ticker: PTKF - Jakarta, Indonesia
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: PTKF
PTKFY OTC Market Information
OTC Other tier stocks are typically less regulated than those listed on major exchanges like NYSE or NASDAQ. This tier includes companies that may not meet the stringent listing requirements of larger exchanges, leading to less visibility and potentially higher risks for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower visibility and less regulatory oversight compared to major exchanges.
- Potential for higher volatility and wider bid-ask spreads.
- Limited access to financial information and disclosures.
- Risks associated with lower trading volumes and liquidity.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market position.
- Understand the regulatory environment affecting the company.
- Evaluate the management team's track record and experience.
- Monitor currency risks associated with the ADR.
- Established brand presence in the Indonesian market.
- Long history of operations since 1966.
- Diverse product offerings and strong distribution network.
PTKFY Healthcare Stock FAQ
What does PT Kalbe Farma Tbk. do?
PT Kalbe Farma Tbk. specializes in the development, manufacturing, and commercialization of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and nutritional products. The company operates through four main divisions, ensuring a comprehensive approach to healthcare solutions in Indonesia.
How does PT Kalbe Farma Tbk. manage patent expiration risks?
PT Kalbe Farma Tbk. mitigates patent expiration risks by focusing on a diverse portfolio of generic and branded medications. The company invests in research and development to innovate and extend product life cycles, while also preparing to introduce new products to offset revenue losses from expiring patents.
What are the main risks for PTKFY?
Main risks for PT Kalbe Farma Tbk. include currency fluctuations that may affect the valuation of its ADR, regulatory changes that could impact product approvals, and economic downturns that might reduce consumer spending on healthcare products. Additionally, intense competition from both local and international pharmaceutical companies poses a continuous threat to market share.
What are the key factors to evaluate for PTKFY?
PT Kalbe Farma Tbk. (PTKFY) holds an AI score of 47/100 (low). P/E: 9.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does PTKFY data refresh on this page?
PTKFY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PTKFY's recent stock price performance?
PT Kalbe Farma Tbk. (PTKFY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in Indonesia's pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PTKFY overvalued or undervalued right now?
PT Kalbe Farma Tbk. (PTKFY) trades at 9.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PTKFY?
Before investing in PT Kalbe Farma Tbk. (PTKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profile and financial metrics.